

**Curriculum Vitae**  
**Patrick A. Oliver, MD**

**CONTACT INFORMATION:**

**Name** Patrick A. Oliver

**Office Addresses** **Mind Peace, LLC**

**MindPeace Clinic – Arlington**  
1600 Wilson Blvd, Suite 320  
Arlington, VA 22209 USA  
**Telephone** 703 340 1454  
**Fax #** 703 832 9288

**MindPeace Clinic – Richmond**  
7110 Forest Ave, Suite 203  
Richmond, VA 23226 USA  
**Telephone** 804 286 0082  
**Fax #** 703 832 9288

**MindPeace Clinic – Norfolk**  
6275 E. Virginia Beach Blvd, Suite 303  
Norfolk, VA 23502 USA  
**Telephone** 757 337 1525  
**Fax #** 703 832 9288

**Email** [POliverMD@MindPeaceClinic.com](mailto:POliverMD@MindPeaceClinic.com)

**Office Address** **Infusion Solutions, LLC**  
7110 Forest Ave, Suite 203  
Richmond, VA 23226 USA  
**Telephone** 804 442 3558  
**Fax #** 804 554 5848

**Email** [POliverMD@TheInfusionSolution.com](mailto:POliverMD@TheInfusionSolution.com)

**Office Address** **Clinical Research Partners, LLC**

**Patrick A. Oliver, MD**  
**Richard L. Bennett, Jr., MD**  
**Robert S. Call, MD**  
**Banks W. Turner, MD**  
7110 Forest Avenue, Suite 201, 100, 203  
Richmond, VA 23226 USA  
**Telephone / 24hr #** 804 477 3045 / 804 920 1413  
**Fax #** 804 477 3374

**Email** [POliverMD@ClinicalReserchRVA.com](mailto:POliverMD@ClinicalReserchRVA.com)

## PROFESSIONAL BACKGROUND

### Group and Hospital Affiliations, MD

- Mind Peace Clinics – *Medical Director*, Arlington, Norfolk & Richmond, VA 1/2017 – Present  
**Ketamine Therapeutics Treatments**
  - Founder of Mind Peace, LLC.
  - Administered thousands of Ketamine infusions to hundreds of patients
  - Treating patients with Ketamine & Esketamine for the following indications:
    - Suicidal Ideation
    - Mood Disorders (Depression, Anxiety & Obsessive-Compulsive Disorder (OCD))
    - Complex Regional Pain Syndrome (CRPS) & Reflex Sympathetic Dystrophy (RSD)
    - Chronic Headaches (Migraines, Trigeminal Neuralgia)
    - Post-Traumatic Stress Disorder (PTSD)
- Infusion Solutions, LLC - *Medical Director*, Richmond, VA 1/2020 – Present
- Clinical Research Partners, LLC – *Investigator*, Richmond, VA 9/2018 – Present
- Southside Regional Medical Center (SRMC) – Petersburg, VA 6/2014 – Present
- Medical College of Virginia (MCV) Emergency Department – Richmond, VA 4/2014 – 12/2017
- Bon Secours Memorial Regional Medical Center (MRMC) – Mechanicsville, VA 8/2010 – 1/2015
- Bon Secours Mary Immaculate Hospital (MIH) – Newport News, VA 9/2010 – 7/2014
- Rappahannock General Hospital (RGH) – Kilmarnock, VA 2/2011 – 6/2013
- Centra Southside Community Hospital (CES) – Farmville, VA 10/2010 – 1/2012
- St. Luke’s Hospital and Health Network (SLHN) – Bethlehem, PA 6/2007 – 6/2010

### Certifications, Licenses & Training

- NPI Number: **1154518751**
- Commonwealth of Virginia – Medical Physician & Surgeon License – **Active: 0101247379**
- CITI Collaborative Institutional Training Initiative – web-based training
- Curriculum: Good Clinical Practice, Human Subjects in Research, HIPAA
- American Board of Emergency Medicine – *Diplomat*
- Controlled Substance Registration Certificates, Drug Enforcement Administration – Active
- Commonwealth of Pennsylvania – Medical Physician & Surgeon License – Inactive
- Medical Command Physician – Pennsylvania Department of Health
- Advanced Ultrasound Course – American Academy of Emergency Medicine
- Advanced Airway Course – Lehigh Valley Hospital – Allentown, PA
- HIPPA Course Certification
- Child Abuse Course Certification
- Commonwealth of Virginia – Emergency Vehicle Operators Course Certificate (EVOC)
- Advanced Cardiac Life Support (ACLS)
- Advanced Trauma Life Support (ATLS)
- Pediatric Advanced Life Support (PALS)

### Academic Affiliation

- **Medical College of Virginia, Virginia Commonwealth University**
  - *Assistant Clinical Professor*, Department of Internal Medicine 8/2012 – 12/2016
  - *Clinical Instructor*, Department of Emergency Medicine 4/2014 – 12/2017

### Professional Associations

- Medical Society of Virginia (MSV) 2004 – Present
- Richmond Academy of Medicine (RAM) 2004 – Present
- American Academy of Emergency Medicine (AAEM) 2008 – Present
- American Society of Ketamine Physicians (ASKP) 2017 – Present
- Washington Psychiatric Society (WSP) (Associate Member) 2017 – Present
- American Medical Association (AMA) 2003 – 2011
- American College of Emergency Physicians (ACEP) 2006 – 2010
- Society of Academic Emergency Medicine (SAEM) 2009 – 2010
- Pennsylvania College of Emergency Physicians (PACEP) 2007 – 2010
- Virginia College of Emergency Physicians (VACEP) 2005 – 2007

## BUSINESS EXPERIENCE

### Pentico Solutions, Inc.

10/2001 – 5/2003

- **Consultant – Centocor, Inc** (subsidiary of Johnson and Johnson) – Malvern, Pennsylvania
  - Designed and implemented a custom web-based database tracking system, QUEST, for the Research and Development Global Contracting (RDGC) Function
  - Advised and assisted a Process Excellence (Six Sigma methodology) effort for RDGC
  - Implemented a Project Management Methodology (PMM) for RDGC Leadership that was consistent with the overall Centocor PMM & the Project Management Institute's Body of Knowledge (PMBOK)
  - Represented the RDGC prospective within the Project Management and Portfolio Planning (PM&PP) Department Working Group for a multi-Johnson & Johnson Enterprise Resource and Project Management System (ERPM), which is an OPX2 based Operating System
  - Managed contracts and coordinated negotiations for four (Phase II & III) Clinical Trials
- **Consultant – AstraZeneca Pharmaceuticals, LP** – Wilmington, Delaware
  - Led design and development of the Strategic Staffing Process Initiative Presentation
  - Drafted the process for policy development within Human Resources from industry best practices

### KPMG, LLP – Public Services Practice

10/1998 – 5/2001

- **Consultant – Federal Services** – Crystal City & Pentagon, Virginia
  - Led Performance Based Budget Cycle Implementation for the US Army
  - Developed Performance Based Budget for the Foreign Military Sales Administrative Trust Fund
  - Facilitated development of security cooperation performance metrics and review methodology
  - Acted as technical lead for multifaceted e-Learning solution to educate decision makers and train participants
  - Facilitated development and design of standardized budget submission templates for all participation agencies
- **Consultant – State and Local Government** – Sacramento, California
  - Aided in planning and implementation of the California Board of Control's Strategic Business Plan, which utilized the Balanced Scorecard Approach
  - Led an organization review and analysis of the Administrative Unit for the County of Sacramento Transportation Division
  - Conducted a thorough management review of the Sacramento County Probation Department
  - Assisted in the performance audit of the Administrative Law Bureau of the California Department of Insurance (CDI)
  - Assisted in the development of the CDI Holocaust Restitution Effort Budget Change Proposal
  - Compiled statistics and drafted the requisite Status Report regarding the CDI's Holocaust Restitution Effort to the California Legislature
  - Established and implemented the internal process and procedures for performing Market Conduct Examinations for CDI
  - Participated in the on-site evaluation of an insurance company's refund process pursuant to California Proposition 103 on behalf of CDI
  - Developed sections of a training seminar for the Idaho State Department of Health and Human Services' Division of Medicaid Quality Insurance and Management Committees
  - Performed Y2K systemic review for the City of Sacramento's Public Works and Administration Departments

## EMERGENCY MEDICAL SERVICES EXPERIENCE

- **Lakeside Volunteer Rescue Squad** 4/2015 – 4/2020
  - Operational Medical Director (OMD)
- **Tuckahoe Volunteer Rescue Squad** 11/1994 – 6/2007
  - Advanced Life Support Provider & Preceptor
  - Crew Chief – Pump Road Station
  - Bicycle Team Founding Member
  - Uniform Committee Chair
  - Vehicular Extrication Attendant
- **Commonwealth of Virginia, Office of Emergency Medical Services** 1997
  - Facilitated the execution of a “Table Top” exercise of Emergency Response to a Nuclear Detonation of at a Central Virginia Theme Park with Federal, State and Local Agencies and Organizations
  - Reviewed and Amended Commonwealth of Virginia Emergency Services Center Standard Operating Procedures and Response Scenarios
  - Lead tactical evaluation of Triennial Emergency Services Drill at Richmond International Airport
- **Commonwealth of Virginia, Office of Emergency Medical Services** 1996 – 1998
  - Fairbanks RJ, Goyal M, Gehr TWB. Renal Failure & Dialysis Patients. VEMS-TV (“EMSAT” educational program). Office of Emergency Medical Services, Virginia Department of Health, Richmond, VA. Broadcast and video release date: December 1998. Coy, T.
  - Gun Shot Wounds in Rural Environments. VEMS-TV (“EMSAT” educational program). Office of Emergency Medical Services, Virginia Department of Health, Richmond, VA. Broadcast and video release date: October, 1996.

## ACADEMIC BACKGROUND

### Education

- **Emergency Medicine Residency Program** – Saint Luke’s Hospital, Bethlehem, Pennsylvania
  - Allopathic Emergency Medicine Program 6/2007 – 6/2010
- **Medical College of Virginia – Virginia Commonwealth University**, Richmond, Virginia
  - Doctor of Medicine 8/2003 – 5/2007
- **College of General Studies – University of Pennsylvania**, Philadelphia, Pennsylvania
  - Post Baccalaureate Pre-Health Program 5/2001 – 5/2003
- **Jepson School of Leadership Studies – University of Richmond**, Richmond, Virginia
  - Bachelor of Arts 8/1994 – 5/1998
  - Double majors in Leadership Studies and Speech Communication

### Awards & Honors

- “Going the Extra Mile!” Recognition – St. Luke’s Hospital 2007
- Dean’s List – University of Richmond Spring 1998
- Greek Unsung Hero Award – University of Richmond’s Interfraternity Council 1998
- Intermediate Honors – University of Richmond Spring 1996
- Sophomore Outstanding Leadership Award – ODK December 1996
- Eagle Scout Award with Bronze and Gold Palms March 1992

## Presentations and Lectures

- Oliver, P. Ketamine for the Treatment of Mood Disorders and Suicidal Ideation  
Riverside/VCU Family Medicine Residency Program: Grand Rounds 4 March 2021
- Oliver, P. How does Ketamine Treat Depression  
EVMS Psychiatry Residency Program: Grand Rounds 9 September 2020
- Oliver, P. Ketamine for the Treatment of Mood Disorders & Suicidal Ideation  
University of Virginia Grand Rounds 25 September 2018
- Oliver, P. Pre-Hospital Emergency Airways.  
VCU Emergency Medicine Residency Program: Grand Rounds 13 May 2015
- Oliver, P. Doctors and Dollars. AAEM Scientific Assembly: PK Lecture 3 March 2015
- Oliver, P. Doctors and Dollars. M2 Orientation for MCV School of Medicine 15 July 2012
- Oliver P, Ornato J, Regan C, Brown W, Stolfus J: Correlation Between Heart  
Rate in Pre-Hospital Patients with Atrial Fibrillation with Rapid Ventricular  
Response and Blood Serum Magnesium Levels 15 February 2010
- Oliver, P. Case Presentation: Deep Vein Thrombosis 27 August 2009
- St. Luke's Emergency Medicine Residency Program Grand Rounds
- Oliver P, EMS Presentation: Prehospital Hypothermia 23 October 2008
- Combined St. Luke's Emergency Medicine Residency Program Grand Rounds  
and Lehigh Valley Emergency Medical Services Lecture
- Oliver P, Eberhardt M, Clay E: Attending Social Gatherings and Grand Rounds  
Has No Effect on the Opinions of Candidates Interviewing for Emergency  
Medicine Residency Positions.
  - AAEM – 15th Annual Scientific Assembly 2 March 2009
  - St. Luke's Hospital and Health Network Research Symposium 18 June 2009
- Oliver, P. Street Drugs: What Basic Life Support Providers Need to Know 10 November 2008
- Lehigh University Emergency Medical Service Response Team Lehigh University
- Oliver, P. Trauma Case Presentation: Central Spinal Cord Injury 21 January 2009
- St. Luke's Hospital Trauma Conference
  - Oliver, P. Shock and Resuscitation SLHN Surgical Critical Care Conference 23 July 2009
  - Oliver, P. Sepsis and Septic Shock SLHN Surgical Critical Care Conference 16 July 2009
- Oliver, P. Case Presentation: Aortic Thromboembolism 28 November 2007
- St. Luke's Emergency Medicine Program Grand Rounds
  - Oliver, P. Case Presentation: Ectopic Pregnancy 1 November 2007
  - St. Luke's Emergency Medicine Program Grand Rounds
- MCV Emergency Medicine Residency Program Teaching Conference
  - Oliver, P. Case Presentation: Hyperkalemia September 2006

## PERSONAL

### Activities

- Richmond Ambulance Authority (RAA) – Special Medical Advisor to UREMS 2011 – Present
- Ducatista 2005 – Present
- Scuba Diving (NAUI Certification 1997) 1997 – Present
- MCV Class of 2007 Student Government – Alumni Representative 2004 – 2007
- MCV Alumni Annual Fund – Chair and Vice Chair 2004 – 2005
- Emergency Medical Resident's Association – MCV Med Student Representative 2005 – 2007
- MCV Emergency Medical Student Association – President 2006 – 2007
- VCU Intramural Sports: Racquetball, Soccer, Floor Hockey 2003 – 2007
- Spider Advanced Volunteer Emergency Rescue Service (SAVERS) – Founder 1997 – 1998

## CLINICAL RESEARCH EXPERIENCE – Investigator

- 2020 **D8110C00001:** A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19  
**AstraZeneca → D8110C00001 → Phase 3**
- 2020 **D3256C00001:** A Phase 2 Multinational, Randomized, Double-blind, Parallel-group, 16-week Placebo-controlled Study with a 36-week Extension to Investigate the Use of Benralizumab for Patients with Moderate to Severe Atopic Dermatitis Despite Treatment with Topical Medications (The HILLIER Study)  
**AstraZeneca → D8110C00001 → Phase 2**
- 2020 **20-AVP-786-306:** A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of agitation in patients with dementia of the Alzheimer's type  
**Avanir → 20-AVP-786-306 → Phase 3**
- 2020 **ARQ-151-107:** An Open Label, Phase 1, Maximal Usage Pharmacokinetics and Safety Study of ARQ-151 Cream 0.3% Administered QD in Adolescent and Adult Subjects with Chronic Plaque Psoriasis  
**Arcutis → ARQ-151-107 → Phase 1**
- 2020 **INCB 18424-308 EXT:** A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants with Vitiligo  
**Incyte → INCB 18424-308 EXT → Phase 3**
- 2020 **CSP-18-0002:** DERMaSensor Study of Primary Care Physician use of an adjunctive tool utilizing Elastic-Scattering Spectroscopy (ESS) on skin lesions suggestive of skin cancer (DERM-SUCCESS)  
**DermaSensor, Inc. → CSP-18-0002 → Device**
- 2020 **FB825CLRS01:** A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate Efficacy, Pharmacokinetics, and Safety of Multiple Intravenous Doses of FB825 in Adults with Atopic Dermatitis  
**Fountain / Oneness Biotech Ltd. → FB825CLRS01 → Phase 2**
- 2020 **AMTX100-AD-01:** A two part, Phase I/II, Multi-center, double-blind, randomized, vehicle-controlled study of the safety and efficacy of topically applied AMTX100 CF in adult patient with mild to moderate atopic dermatitis  
**Amyrx Therapeutics → AMTX100-AD-01 → Phase 1/2**
- 2020 **DS107G-05-AD3:** A Randomized, Double-blind, Placebo-controlled Study to assess the Efficacy and Safety of Orally Administered DS107 in Adult Patients with Moderate to Severe Atopic Dermatitis  
**DS Biopharma → DS107G-05-AD3 → Phase 2**
- 2020 **M19-850:** A Phase 3b, open-label treatment extension study of Upadacitinib for the treatment of adult subjects with moderate to severe atopic dermatitis who completed treatment in Study M16-046  
**Abbvie → M19-850 → Phase 3b**
- 2019 **V503-049:** A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-like Particle Vaccine, in the prevention of oral persistent infection with HPV Types 16, 18, 31, 33, 45, 52, or 58 in adult males, 20 to 45 years of age  
**Merck → V503-049 → Phase 3**

- 2019 **ARQ-151-306:** A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.3% in Subjects with Chronic Plaque Psoriasis who have Completed Preceding Studies ARQ-151-301 or ARQ-151-302  
**Arcutis Biotherapeutics Inc. → ARQ-151-306 → Phase 3**
- 2019 **ARQ-151-302:** A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.3% Administered QD in Subjects with Chronic Plaque Psoriasis  
**Arcutis Biotherapeutics Inc. → ARQ-151-302 → Phase 3**
- 2019 **ARQ-154-204:** A Phase 2b, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Adolescents and Adults with Scalp and Body Psoriasis  
**Arcutis Biotherapeutics Inc. → ARQ-151-204 → Phase 2b**
- 2019 **LIN-MD-64:** A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Safety and Efficacy Study of Linaclotide Administered Orally to Children, Ages 6 to 17 Years, With Functional Constipation (FC)  
**Allergan → LIN-MD-64 → Phase 3**
- 2019 **LIN-MD-66:** A Phase 3, Open-label, Long-term Safety Study of Oral Linaclotide Administered to Pediatric Participants with Functional Constipation (FC) or Irritable Bowel Syndrome with Constipation (IBS-C)  
**Allergan → LIN-MD-66 → Phase 3**
- 2019 **LIN-MD-67:** A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Sequential, Ascending, Multidose Study to Evaluate the Safety and Efficacy of Linaclotide in Pediatric Participants (Age 2 to 5 Years) with Functional Constipation  
**Allergan → LIN-MD-67 → Phase 2**
- 2019 **M16-046:** A Phase 3b Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Adult Subjects with Moderate to Severe Atopic Dermatitis.  
**Abbvie → M16-046 → Phase 3b**
- 2019 **INCB 18424-307:** A Phase 3, Double-Blind, Randomized, Vehicle Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants with Vitiligo  
**Incyte Corporation → INCB 18424-307 → Phase 3**
- 2019 **CQBW251B2201:** A 24-week multi-center, double-blind, placebo-controlled dose-range finding study to investigate the efficacy and safety of oral QBW251 in COPD patients on triple inhaled therapy (LABA/LAMA/ICS)  
**Novartis Pharmaceuticals → CQBW251B2201 → Phase 2b**
- 2019 **APD334-201:** A Multicenter, Randomized, Double-Blinded, Placebo-Controlled 16-Week Study (with a 52-Week Open-Label Extension) to Assess the Safety and Efficacy of Etrasimod in Subjects with Moderate-to-Severe Atopic Dermatitis  
**Arena Pharmaceuticals, Inc. → APD334-201 → Phase 2**
- 2019 **ARQ-151-212:** A Phase 2, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% and ARQ-151 Cream 0.15% Administered QD in Adolescent and Adult Subjects with Atopic Dermatitis  
**Arcutis, Inc. → ARQ-151-212 → Phase 2**
- 2019 **CR845-210501:** A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate The Efficacy And Safety Of Oral Difelikefalin (Cr845) For Moderate To Severe Pruritus In Adult Subjects With Atopic Dermatitis  
**Cara Therapeutics Inc. → CR845-210501 → Phase 2**

- 2019 **ANB020-005:** A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profile of ANB020 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis  
**AnaptysBio, Inc. → ANB020-005 → Phase 2b**
- 2019 **CP 0418 SS-P2 051:** Open-Label Study of the Pharmacokinetics and Safety Including HPA Axis Suppression Potential of Clobetasol Topical Oil in Pediatric Subjects with Moderate to Severe Atopic Dermatitis  
**Hill Dermaceuticals, Inc. → CP 0418 SS-P2 051 → Phase 1/2**
- 2019 **INCB 18424-103:** A Maximum Use Trial of Ruxolitinib Cream in Adolescent and Adult Participants with Atopic Dermatitis  
**Incyte Corporation → INCB 18424-103 → Phase 1**
- 2019 **V01-124A-501:** A Phase 1b, Open-Label Randomized Study Evaluating the Safety and Systemic Pharmacokinetics of Topically Applied IDP-124 Lotion in Pediatric Subjects with Atopic Dermatitis under Maximal Use Conditions  
**Bausch Health → V01-124A-501 → Phase 1b**
- 2019 **RD.03.SPR.118169:** A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Moderate to Severe Atopic Dermatitis  
**Galderma → RD.06.SPR.118169 → Phase 3**
- 2019 **RD.06.SPR.116912:** A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics and Safety of Nemolizumab (CD14152) in Adolescent Subjects (12-17 years) with Moderate-to-Severe Atopic Dermatitis and Associated Pruritus  
**Galderma → RD.06.SPR.116912 → Phase 2**
- 2019 **ASN002AD-201-EXT:** A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the long-term Safety, Tolerability and Efficacy of ASN002 in Subjects with Moderate to Severe Atopic Dermatitis.  
**ASANA → ASN002AD-201-EXT → Phase 2**
- 2018 **ASN002AD-201:** A Randomized, Double-Blind, Placebo-Controlled, Phase 2B Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects with Moderate to Severe Atopic Dermatitis CODE NUMBER: ASN002AD-201 (RADIANT)  
**ASANA → ASN002AD-201 → Phase 2b**
- 2019 **GS40868:** A phase II open-label extension study to evaluate the long-term safety and efficacy of Fenebrutinib in patients previously enrolled in a Fenebrutinib chronic spontaneous urticaria study  
**Genentech → GS40868 → Phase 2**
- 2019 **GS39684:** A Phase II, multicenter, randomized, double-blind, placebo-controlled pilot and dose-ranging study of GDC-0853 in patients with refractory chronic spontaneous Urticaria (CSU)  
**Genentech → GS39684 → Phase 2**
- 2019 **R3500-AD-1798:** A randomized, double-blind, placebo-controlled, phase 2A study to assess the efficacy and safety of REGN3500 monotherapy and combination of REGN3500 plus Dupilumab in adult patients with moderate-to-severe atopic dermatitis  
**Regeneron → R3500-AD-1798 → Phase 2a**
- 2019 **INCB 18424-304:** A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults with Atopic Dermatitis  
**INCYTE → INCB 18424-304 → Phase 3**



- 2019 **MVT-601-035:** An International Phase 3 Double-Blind, Placebo-controlled, Randomized Withdrawal Study of Relugolix Co-administered with Estradiol and Norethindrone Acetate in Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids  
**Myovant Sciences** → **MVT-601-035** → **Phase 3**
- 2019 **GS40965:** A Phase II, randomized, double blind, placebo controlled multicenter study to assess the efficacy and safety of MSTT1041A in patients with moderate to severe atopic dermatitis  
**Genentech** → **GS40965** → **Phase 2**
- 2019 **MTI-107:** An open-label long-term safety study of Serlopitant for the treatment of pruritis  
**Menlo** → **MTI-107** → **Phase 3**
- 2019 **EX9536-4388:** SELECT - Semaglutide effects on cardiovascular outcomes in people with overweight or obesity. IND# 126 360  
**Novo Nordisk** → **EX9536-4388** → **Phase 3b**
- 2019 **C3718-302:** A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial of Oral IW-3718 Administered to Patients with Gastroesophageal Reflux Disease while receiving Proton Pump Inhibitors  
**Ironwood** → **C3718-302** → **Phase 2**
- 2019 **GBR 830-204:** A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of GBR 830 in Adult Subjects with Moderate to Severe Atopic Dermatitis  
**Glenmark Pharmaceuticals** → **GBR 830-204** → **Phase 2b**
- 2019 **FLSA-P100/50-PVCL-2:** A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100µg and Salmeterol Xinafoate 50µg Inhalation Powder Compared with Advair Diskus® 100/50 in Subjects with Asthma  
**West-Ward Columbus Inc.** → **FLSA-P100/50-PVCL-2** → **Phase Bioequivalence**
- 2019 **NN9536-4376:** Protocol Title: Effect and safety of Semaglutide 2.4 mg once-weekly in subjects with overweight or obesity who have reached target dose during run-in period  
**Novo Nordisc** → **NN9536-4376** → **Phase 3a**
- 2019 **D5180C00007:** A Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma (NAVIGATOR)  
**AstraZeneca** → **D5180C00007** → **Phase 3**
- 2019 **MVT-601-3002:** LIBERTY 2: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Co-Administered with and without Low-Dose Estradiol and Norethindrone Acetate in Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids  
**MYOVANT** → **MVT-601-3002** → **Phase 3**
- 2019 **PT001102:** A Randomized, Double-Blind, Parallel Group, Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects with Persistent Asthma  
**Pearl Therapeutics** → **PT001102** → **Phase 2/3**
- 2019 **K-877-302:** Pemaafibrate to Reduce cardiovascular Outcomes by reducing triglycerides IN patients with diabetes (PROMINENT)  
**Kowa Research Institute, Inc.** → **K-877-302** → **Phase 3**
- 2018 **KPL-716-C001:** A Phase Ib, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Repeated Doses of KPL-716  
**Kiniksa** → **KPL-716-C001** → **Phase 1b**

2018

**MVT-601-3003 LIBERTY EXTENSION:** An International Phase 3 Open-Label, Single-Arm, Long-Term Efficacy and Safety Extension Study to Evaluate Relugolix Co-Administered with Low-Dose Estradiol and Norethindrone Acetate in Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids  
**Myovant → MVT-601-3003 → Phase 3**